摘要
纳曲酮是一种竞争性阿片受体拮抗剂，被批准作为酒精依赖和阿片类药物成瘾的支持性治疗。在每日50-100mg的剂量下，纳曲酮在皮肤病学中用于标签外用于治疗拔毛癖和不同类型的瘙痒症。在每天低至1-5毫克的剂量下，纳曲酮表现出免疫调节作用，即调节Toll样受体信号传导，减少促炎细胞因子（肿瘤坏死因子，白细胞介素-6，白细胞介素-12）的释放，抑制T淋巴细胞增殖，降低 - 调节趋化因子受体和粘附分子的表达。已经报道了标准和低剂量纳曲酮在各种皮肤病中的功效。这些疾病包括家族性良性慢性天疱疮（Hailey-Hailey病），皮肌炎，系统性硬化症，牛皮癣和扁平苔癣。乐观的初步研究结果，低廉的治疗费用和良好的耐受性使得纳曲酮成为皮肤病学中一种很有前景的替代疗法或辅助药物。
关键词: 脱发，低剂量纳曲酮，阿片类生长因子，瘙痒症，牛皮癣，toll样受体。
图形摘要
[2]
Bisaga A, Mannelli P, Sullivan MA, et al. Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies. Am J Addict 2018; 27: 177-87.
[3]
Goh ET, Morgan MY. Review article: Pharmacotherapy for alcohol dependence - the why, the what and the wherefore. Aliment Pharmacol Ther 2017; 45: 865-82.
[4]
Grandone A, Di Sessa A, Umano GR, Toraldo R, Miraglia Del Giudice E. New treatment modalities for obesity. Best Pract Res Clin Endocrinol Metab 2018; 32: 535-49.
[5]
Lee NK, Jenner L, Harney A, Cameron J. Pharmacotherapy for amphetamine dependence: A systematic review. Drug Alcohol Depend 2018; 191: 309-37.
[6]
Schmitz JM, Lindsay JA, Green CE, Herin DV, Stotts AL, Moeller FG. High-dose naltrexone therapy for cocaine-alcohol dependence. Am J Addict 2009; 18: 356-62.
[7]
Mouaffak F, Leite C, Hamzaoui S, et al. Naltrexone in the treatment of broadly defined behavioral addictions: A review and meta-analysis of randomized controlled trials. Eur Addict Res 2017; 23: 204-10.
[8]
Guerdjikova AI, Walsh B, Shan K, et al. Concurrent improvement in both binge eating and depressive symptoms with Naltrexone/ Bupropion therapy in overweight or obese subjects with major depressive disorder in an open-label, uncontrolled study. Adv Ther 2017; 34: 2307-15.
[9]
Roy A, Roy M, Deb S, Unwin G, Roy A. Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: a systematic review. J Intellect Disabil Res 2015; 59: 293-06.
[10]
Brune A, Metze D, Luger TA, Stander S. Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients. Hautarzt 2004; 55: 1130-6.
[12]
Li Z, You Y, Griffin N, Feng J, Shan F. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. Int Immunopharmacol 2018; 61: 178-84.
[13]
Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)-review of therapeutic utilization. Med Sci (Basel) 2018; 6E82
[14]
Patten DK, Schultz BG, Berlau DJ. The safety and Efficacy of Low-dose Naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s Disease, and other chronic pain disorders. Pharmacotherapy 2018; 38: 382-9.
[15]
Turel AP, Oh KH, Zagon IS, McLaughlin PJ. Low dose Naltrexone for treatment of multiple sclerosis: A retrospective chart review of safety and tolerability. J Clin Psychopharmacol 2015; 35: 609-11.
[16]
Parker CE, Nguyen TM, Segal D, MacDonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2018; 4CD010410
[17]
Metyas S, Chen CL, Yeter K, Solyman J, Arkfeld DG. Low dose Naltrexone in the treatment of fibromyalgia. Curr Rheumatol Rev 2018; 14: 177-80.
[18]
Raknes G, Smabrekke L. A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteristics, and dispense patterns. A drug utilization cohort study. Pharmacoepidemiol Drug Saf 2017; 26: 136-42.
[19]
Atanaskova Mesinkovska N. Emerging unconventional therapies for Alopecia Areata. J Investig Dermatol Symp Proc 2018; 19: S32-3.
[20]
Plein LM, Rittner HL. Opioids and the immune system - friend or foe. Br J Pharmacol 2018; 175: 2717-25.
[21]
Bigliardi PL, Dancik Y, Neumann C, Bigliardi-Qi M. Opioids and skin homeostasis, regeneration and ageing - What’s the evidence? Exp Dermatol 2016; 25: 586-91.
[22]
Ludwig MD, Zagon IS, McLaughlin PJ. Featured article: Serum [Met(5)]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone. Exp Biol Med (Maywood) 2017; 242: 1524-33.
[23]
Ramanathan S, Panksepp J, Johnson B. Is fibromyalgia an endocrine/endorphin deficit disorder? Is low dose naltrexone a new treatment option? Psychosomatics 2012; 53: 591-4.
[24]
Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses 2009; 72: 333-7.
[25]
Kumar K, Singh SI. Neuraxial opioid-induced pruritus: An update. J Anaesthesiol Clin Pharmacol 2013; 29: 303-7.
[26]
Phan NQ, Bernhard JD, Luger TA, Stander S. Antipruritic treatment with systemic mu-opioid receptor antagonists: a review. J Am Acad Dermatol 2010; 63: 680-8.
[28]
Trigo JM, Martin-Garcia E, Berrendero F, Robledo P, Maldonado R. The endogenous opioid system: a common substrate in drug addiction. Drug Alcohol Depend 2010; 108: 183-94.
[29]
Le Merrer J, Becker JA, Befort K, Kieffer BL. Reward processing by the opioid system in the brain. Physiol Rev 2009; 89: 1379-412.
[30]
Ikemoto S. Brain reward circuitry beyond the mesolimbic dopamine system: a neurobiological theory. Neurosci Biobehav Rev 2010; 35: 129-50.
[31]
McLaughlin PJ, Cain JD, Titunick MB, Sassani JW, Zagon IS. Topical Naltrexone is a safe and effective alternative to standard treatment of diabetic wounds. Adv Wound Care (New Rochelle) 2017; 6: 279-88.
[32]
Albers LN, Arbiser JL, Feldman RJ. Treatment of hailey-hailey disease with Low-dose Naltrexone. JAMA Dermatol 2017; 153: 1018-20.
[33]
Neumann C, Bigliardi-Qi M, Widmann C, Bigliardi PL. The delta-opioid receptor affects epidermal homeostasis via ERK-dependent inhibition of transcription factor POU2F3. J Invest Dermatol 2015; 135: 471-80.
[34]
Bigliardi PL, Neumann C, Teo YL, Pant A, Bigliardi-Qi M. Activation of the delta-opioid receptor promotes cutaneous wound healing by affecting keratinocyte intercellular adhesion and migration. Br J Pharmacol 2015; 172: 501-14.
[35]
Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol 2014; 33: 451-9.
[36]
Cant R, Dalgleish AG, Allen RL. Naltrexone inhibits IL-6 and TNFalpha production in human immune cell subsets following stimulation with ligands for intracellular toll-like Receptors. Front Immunol 2017; 8: 809.
[37]
Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of Low-Dose Naltrexone for fibromyalgia. Biomedicines 2017; 5E16
[38]
Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood) 2011; 236: 1036-50.
[39]
Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell 2009; 20: 319-27.
[40]
Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Immunobiology 2011; 216: 173-83.
[41]
Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases. Immunobiol 2011; 216: 579-90.
[42]
McLaughlin PJ, McHugh DP, Magister MJ, Zagon IS. Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis. BMC Immunol 2015; 16: 24.
[43]
Vijay K. Toll-like receptors in immunity and inflammatory diseases: Past, present, and future. Int Immunopharmacol 2018; 59: 391-412.
[44]
Toubi E, Vadasz Z. Innate immune-responses and their role in driving autoimmunity. Autoimmun Rev 2019; 18: 306-11.
[45]
Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci 2008; 28: 20-9.
[46]
Deng H, Xiao H. The role of the ATP2C1 gene in Hailey-Hailey disease. Cell Mol Life Sci 2017; 74: 3687-96.
[47]
Farahnik B, Blattner CM, Mortazie MB, et al. Interventional treatments for Hailey-Hailey disease. J Am Acad Dermatol 2017; 76: 551-8.
[48]
Ibrahim O, Hogan SR, Vij A, Fernandez AP. Low-Dose Naltrexone treatment of familial benign pemphigus (Hailey-Hailey Disease). JAMA Dermatol 2017; 153: 1015-7.
[49]
Campbell V, McGrath C, Corry A. Low-dose naltrexone: a novel treatment for Hailey-Hailey disease. Br J Dermatol 2018; 178: 1196-8.
[50]
Kollman N, Bass J. Generalized familial benign chronic pemphigus (Hailey-Hailey disease) treated successfully with low-dose naltrexone. JAAD Case Rep 2018; 4: 725-7.
[51]
Cao S, Lilly E, Chen ST. Variable response to Naltrexone in patients with Hailey-Hailey Disease. JAMA Dermatol 2018; 154: 362-3.
[52]
Tran T, Chen A, Worswick S. Successful treatment of dermatomyositis with low-dose naltrexone. Dermatol Ther 2018.e12720
[53]
Cappelletti C, Galbardi B, Kapetis D, et al. Autophagy, inflammation and innate immunity in inflammatory myopathies. PLoS One 2014; 9e111490
[54]
Kim GT, Cho ML, Park YE, et al. Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. Clin Rheumatol 2010; 29: 273-9.
[55]
Razykov I, Levis B, Hudson M, Baron M, Thombs BD. Canadian Scleroderma research G. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis: an updated analysis of 959 patients. Rheumatology (Oxford) 2013; 52: 2056-61.
[56]
Therene C, Brenaut E, Sonbol H, et al. Itch and systemic sclerosis: frequency, clinical characteristics and consequences. Br J Dermatol 2017; 176: 1392-3.
[57]
Gourier G, Therene C, Mazeas M, et al. Clinical characteristics of pruritus in systemic sclerosis vary according to the autoimmune subtype. Acta Derm Venereol 2018; 98: 735-41.
[58]
Frech T, Novak K, Revelo MP, et al. Low-dose naltrexone for pruritus in systemic sclerosis. Int J Rheumatol 2011; 2011804296
[59]
Lay J, Carbone SE, DiCello JJ, et al. Distribution and trafficking of the mu-opioid receptor in enteric neurons of the guinea pig. Am J Physiol Gastrointest Liver Physiol 2016; 311: G252-66.
[60]
Immonen JA, Zagon IS, McLaughlin PJ. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing. Exp Biol Med (Maywood) 2014; 239: 1300-9.
[61]
Bridgman AC, Kirchhof MG. Treatment of psoriasis vulgaris using low-dose naltrexone. JAAD Case Rep 2018; 4: 827-9.
[62]
Muller G, Grieshaber R, Talley JF, Riepl M, Fellows D. Compounded low-dose Naltrexone for the treatment of Guttate Psoriasis: A case report. Int J Pharm Compd 2018; 22: 270-8.
[63]
Sikora M, Chrabaszcz M, Maciejewski C, et al. Intestinal barrier integrity in patients with plaque psoriasis. J Dermatol 2018; 45(12): 1468-70.
[64]
Lie M, van der Giessen J, Fuhler GM, et al. Low dose Naltrexone for induction of remission in inflammatory bowel disease patients. J Transl Med 2018; 16: 55.
[65]
Strazzulla LC, Avila L, Lo Sicco K, Shapiro J. Novel treatment using low-dose Naltrexone for Lichen Planopilaris. J Drugs Dermatol 2017; 16: 1140-2.
[66]
Welz-Kubiak K, Reich A. Mediators of pruritus in lichen planus. Autoimmune Dis 2013; 2013941431
[67]
Carrion VG. Naltrexone for the treatment of trichotillomania: a case report. J Clin Psychopharmacol 1995; 15: 444-5.
[68]
Oravecz R, Stuhec M. Trichotillomania successfully treated with risperidone and naltrexone: a geriatric case report. J Am Med Dir Assoc 2014; 15: 301-2.
[69]
Grant JE, Odlaug BL, Schreiber LR, Kim SW. The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. J Clin Psychopharmacol 2014; 34: 134-8.
[70]
De Sousa A. An open-label pilot study of naltrexone in childhood-onset trichotillomania. J Child Adolesc Psychopharmacol 2008; 18: 30-3.
[72]
Carson KL, Tran TT, Cotton P, Sharara AI, Hunt CM. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996; 91: 1022-3.
[73]
Wolfhagen FH, Sternieri E, Hop WC, et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterol 1997; 113: 1264-9.
[74]
Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37: 717-22.
[75]
Mansour-Ghanaei F, Taheri A, Froutan H, et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12: 1125-8.
[76]
Serrano L, Martinez-Escala ME, Zhou XA, Guitart J. Pruritus in cutaneous T-Cell lymphoma and its management. Dermatol Clin 2018; 36: 245-58.
[77]
Jaiswal D, Uzans D, Hayden J, Kiberd BA, Tennankore KK. Targeting the opioid pathway for uremic pruritus: A systematic review and meta-analysis. Can J Kidney Health Dis 2016; 32054358116675345
[78]
Legroux-Crespel E, Cledes J, Misery L. A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology 2004; 208: 326-30.
[79]
Peer G, Kivity S, Agami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996; 348: 1552-4.
[80]
Pauli-Magnus C, Mikus G, Alscher DM, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 2000; 11: 514-9.
[81]
Malekzad F, Arbabi M, Mohtasham N, et al. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol 2009; 23: 948-50.
Article Metrics
69
8
1